Sagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care

1:04:53
 
Share
 

Manage episode 304503862 series 103624
By PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ultimately improve care for their patients with MM. Upon completion of this accredited CE activity, participants should be better able to: Summarize current evidence about the use of novel antibody platforms targeting CD38 and BCMA in relapsed/refractory multiple myeloma (RRMM), including in heavily pretreated disease, Integrate antibody-based therapies into team treatment plans for the management of patients with RRMM, Develop team-based strategies addressing practical aspects of antibody therapy in RRMM, including issues related to dosing/scheduling, unique safety considerations such as neutropenia, infection, and ocular toxicity, and patient and staff education on drug safety/delivery.

301 episodes